Prognostic Value of Combination of Heart-Type Fatty Acid-Binding Protein and Ischemia-Modified Albumin in Patients With Acute Coronary Syndromes and Norma Troponin T Values

Creative Commons License

Cui Liyan C. L., Zhang Jie Z. J., Hu Xiaozhou H. X.

JOURNAL OF CLINICAL LABORATORY ANALYSIS, vol.23, no.1, pp.14-18, 2009 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 23 Issue: 1
  • Publication Date: 2009
  • Doi Number: 10.1002/jcla.20276
  • Journal Name: JOURNAL OF CLINICAL LABORATORY ANALYSIS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.14-18
  • Keywords: acute coronary syndrome, myocardial ischemia, fatty acid-binding proteins, biomarkers, ACUTE MYOCARDIAL-INFARCTION, ST-SEGMENT ELEVATION, UNSTABLE ANGINA, EARLY-DIAGNOSIS, TISSUE-INJURY, PLASMA, MARKER, SERUM, MANAGEMENT, NECROSIS
  • Dokuz Eylül University Affiliated: No

Abstract

Recent studies have suggested that heart-type fatty acid-binding protein (H-FABP) may detect ongoing myocardial damage involved in the progression of acute coronary syndromes (ACS). This study was prospectively designed to examine whether the combination of H-FABP, a marker for ongoing myocardial damage, and ischemia-modified albumin (IMA), a marker for myocardial ischemia, would effectively diagnose patients with ACS. H-FABP values above 1.5 mu g/l can be correctly measured via an ELISA and 6 mu g/l is the currently used cut-off value (1-3). We measured serum H-FABP and IMA of 108 patients on admission within 12 hr after onset of chest pain and normal troponin T. serum samples from ACS group (n=82) had decreased capacity of ACB [64 (61-67) U/ml] compared with non-ACS ischemic chest pain group (n = 26) samples [75 (71-78) U/ml] (P<0.05). The combination of IMA and H-FABP usually had better sensitivity [96.3% (92.2-100%)] (P<0.05) and accuracy [92.6 (87.7-97.5%)] (P<0.05) than when individually used. Thus, the combination of H-FABP and IMA measurements after initiation of chest pain may be highly effective for risk stratification in patients with ACS and normal cardiac troponin T. J. Clin. Lab. Anal. 23:14-18, 2009. (C) 2009 Wiley-Liss, Inc.